Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03126435
Title EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors SynCore Biotechnology Co., Ltd.
Indications

pancreatic adenocarcinoma

Therapies

EndoTAG-1 + Gemcitabine

Gemcitabine

Age Groups: adult | senior
Covered Countries USA | FRA


No variant requirements are available.